Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rama Suresh (NPI 1093731226)

Field	Value
Entity Type	Individual
Organization	Rama Suresh
Address	10 Barnes West Dr
City	Saint Louis
State	MO
ZIP	63141
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 14, 2006

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused medical oncology practice: Total Medicare revenue is $2.1M and there is no Medicaid billing on file, so payer mix is essentially single‑payer Medicare for the claims captured here. The absence of Medicaid activity means state Medicaid competitiveness or penetration cannot be assessed from this dataset.

Revenue is highly concentrated in a small number of biologic and specialty injectable therapies: the precomputed top 3 Medicare codes account for 53.1% of total Medicare revenue, with J9271 accounting for $481.6K (23.8%), J9299 for $363.8K (18.0%), and J2353 for $228.4K (11.3%). This concentration indicates a reliance on high-cost oncology infusions as the main revenue drivers.

The code mix and dominant products point to a practice organized around infusion and oncology therapeutics rather than office-based primary care: high-revenue codes include checkpoint inhibitors (J9271 pembrolizumab, J9299 nivolumab) and depot somatostatin analog therapy (J2353 octreotide depot), alongside chemotherapy administration codes such as 96413 and infusion-continuation codes like G0498. These procedure and drug combinations are characteristic of a clinic delivering complex, clinic-based infusion regimens for cancer and related conditions.

Competitive standing across individual drugs is mixed. For J9271 the provider ranks #1028 of 1841 nationally (43th percentile) and for J9299 ranks #242 of 505 (52th percentile), both labeled as typical or unremarkable volumes nationally, while J2353 ranks #5 of 18 (76th percentile) indicating a stronger relative position for octreotide depot compared with peers. In short, the practice is a modest national participant for checkpoint inhibitors but shows above-typical presence for certain niche agents.

Procedure-level administration patterns further underscore an infusion-centric operation: 96413 shows 634 claims and $62.8K revenue and ranks #355 of 7514 providers nationally (95th percentile), described as notably above typical national volume, and G0498 has 139 claims and $17K revenue and ranks #37 of 896 providers nationally (96th percentile), also notably above typical. Those high percentiles for administration codes suggest the provider delivers chemotherapy/infusion services at volumes above many peers.

The practice uses a range of supportive agents and biosimilars alongside high-cost monoclonal antibodies: notable entries include J1561 ($96.1K), J2506 ($29.2K), Q5119 ($36.3K), Q5107 ($35.4K) and Q5114 ($22K). This mix indicates integration of IVIG or immune‑modulating preparations, growth‑factor support, and adoption of biosimilar oncology agents in routine care delivery.

The provider has an established NPI tenure, enumerated on 2006-07-14 (~20 years ago), which suggests a long-standing presence in the market and the potential for stable referral relationships that support sustained infusion-based revenue. Longevity paired with concentration in specialty infusions is consistent with an experienced oncology practitioner rather than a recently established entrant.

Several codes show benchmarking caveats or small national peer sets that complicate comparison: J9306 is listed as rank #1 of 1 providers nationally (0th percentile; no national peer volume comparison available) and Q5114 is rank #7 of 7 providers nationally (0th percentile), so those ranks reflect very limited peer reporting rather than clear market dominance. Analysts should interpret the standing of low-peer-count codes cautiously when drawing conclusions about competitive positioning.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

64 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,200	$40	$481.6K
J9299	Injection, nivolumab, 1 mg	15,160	$20	$363.8K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	1,410	$160	$228.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	4,320	$40	$164.2K
J0897	Injection, denosumab, 1 mg	8,340	$20	$150.1K
J9306	Injection, pertuzumab, 1 mg	10,920	$10	$131K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	2,530	$40	$96.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	630	$100	$62.8K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	6,230	$10	$62.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	510	$100	$49K

Showing 1–10 of 64

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 64 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Rama Suresh — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

64 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	18	40	9,100	$40	$502K
J9299	8	20	14,170	$20	$360.3K
J9144	19	20	7,200	$40	$308.4K
J2353	2	10	1,100	$160	$225.3K
J9306	1	10	10,920	$10	$129.6K
J1561	9	30	1,650	$40	$87.1K
J0897	26	210	2,400	$20	$82.4K
J9264	7	10	6,500	$10	$69.9K
Q5119	6	10	1,570	$20	$43.6K
Q5107	2	10	1,520	$20	$41K

Showing 1–10 of 64

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rama Suresh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Washington University	MO	Multi-Specialty Clinic/Center	$0	$22M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$14.8M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$10.4M
Washington University	MO	Emergency Care Clinic/Center	$0	$9.1M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$6.9M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.4M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$4M
John Visconti	IL	Medical Oncology Physician	$2.8M	$149.1K
Peter Oppelt	MO	Medical Oncology Physician	$2.5M	$15.8K
Ronald Dean	MT	Emergency Medicine Physician	$2.3M	$2.3K

Nearby Providers

Other providers in the same ZIP code as Rama Suresh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Hospitals East Communities	MO	General Acute Care Hospital	$0	$56.5M
Bayada Home Health Care, Inc.	MO	Home Health Agency	$0	$41.2M
Mercy Clinic East Communities	MO	Internal Medicine Physician	$0	$22.2M
Excel Home Care, Inc.	MO	Home Health Agency	$0	$19.8M
Biotech X-ray Inc	MO	Portable X-ray and/or Other Portable Diagnostic Imaging Supplier	$5.1M	$6M
Western Anesthesiology Associates, Inc.	MO	Anesthesiology Physician	$0	$10.9M
Team Select Home Care Of Missouri, Inc.	MO	Nursing Care Agency	$0	$10.7M
Physician Groups Lc	MO	Multi-Specialty Clinic/Center	$0	$9.8M
Sensory Solutions, LLC	MO	Occupational Therapist	$0	$7.3M
Excel Home Care, Inc.	MO	Home Health Agency	$0	$6.2M

Rama Suresh — Billing Profile & Reimbursement Data

Sign up for Rama Suresh — Billing Profile & Reimbursement Data policy alerts

Rama Suresh — Billing Profile & Reimbursement Data

Sign up for Rama Suresh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References